Leo Zacharski, M.D., and Robert G. Lerner, M.D.

Dr. Zacharski is Professor of Medicine, Dartmouth Medical School, Hanover, New Hampshire, and Associate Chief of Staff, VA Medical Center, White River Junction, Vermont.

In the past three years, Dr. Zacharski has received support from the Department of Veterans Affairs Medical Research Service, and has been on the Speakers' Bureau for Dupont Pharmaceutical and Aventis. In the past three years, Dr. Lerner has served as a consultant for RPR, and has served on the Speakers' Bureau for Pharmacia & Upjohn.

Release Date: 11/21/2000
Termination Date: 11/21/2003

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Upon completion of this Cyberounds^®, the participant should be able to:

• Describe "warfarin resistant" DVT in cancer patients
• Describe several mechanisms by which heparin could alter tumor progression
• Evaluate, critically, new data on the effect of heparin and LMWH on cancer.

 

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity